Aethlon Medical (AEMD) is a pre-revenue clinical-stage medical device company. Under a liquidation lens as of December 31, 2025, estimated recovery to equity is marginally positive but highly dependent on a single asset class: cash. Total assets are $8.1M, of which $7.1M is cash and restricted cash (haircut at 100%), $185K is prepaid expenses (haircut ~80% = $148K), $434K is PP&E (haircut ~60% = $260K), and intangibles of $138 are zeroed. Estimated gross liquidation asset value: approximately $7.5M. Total liabilities at face value are $1.34M, comprised of $1.26M current (accounts payable $469K, operating lease current $331K, other current liabilities $219K, due to related parties ~$238K) and $87K noncurrent operating lease. Net liquidation recovery to equity is approximately $6.2M, consistent with MFFAIS-reported CLV of $5.6M (minor variance attributable to timing or methodology differences). AEMD's equity book value is $6.7M, of which the bulk is APIC of $180M offset by accumulated deficit of $173M. The recovery posture improved quarter-over-quarter: at September 30, 2025 (prior filing), cash was $5.9M and the company carried a $218K Australian R&D tax receivable that was subsequently collected in October 2025, contributing to the $7.1M cash position at December 31, 2025. The December 2025 PIPE offering raised approximately $3.3M gross ($2.3M net of costs), directly bolstering the cash line. Operating cash burn for the nine months ended December 31, 2025 was $5.25M, annualizing to approximately $7M, implying the December 31, 2025 cash balance of $7.1M supports less than 12 months of operations — consistent with management's explicit going-concern disclosure. Two reverse stock splits were executed within the fiscal year (1-for-8 in June 2025, 1-for-10 in October 2025, cumulative 1-for-80), both driven by Nasdaq minimum bid price noncompliance. The company carries no debt other than operating leases with 15 months remaining at $27,983/month combined base rent. There are no goodwill, pension, or production commitments that alter the liability stack. Intangible assets at $138 are effectively zero. The filing discloses 1,435,127 warrants contingent on shareholder approval (not yet obtained as of December 31, 2025) — if exercised at $4.03–$5.04, these could inject $5.8–$7.2M in additional cash but are not on-balance-sheet as of the filing date.
▼ Community Notes